|
|
Volumn 49, Issue 3, 2008, Pages 543-553
|
|
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia
a
|
|
Author keywords
Acute myeloid leukemia; Diphtheria toxin; Interleukin 3; Myelodysplasia
|
|
Indexed keywords
5 AZA 2' DEOXYCYTIDINE;
ALEMTUZUMAB;
ALKYLATING AGENT;
ANTINEOPLASTIC AGENT;
ASPARAGINASE;
AZACITIDINE;
CARBOPLATIN;
CLORETAZINE;
CYCLOPHOSPHAMIDE;
CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE;
CYCLOSPORIN;
CYTARABINE;
DAUNORUBICIN;
DIPHTHERIA TOXIN INTERLEUKIN 3 FUSION PROTEIN;
ETOPOSIDE;
FLUDARABINE;
GEMCITABINE;
GEMTUZUMAB OZOGAMICIN;
IDARUBICIN;
IMATINIB;
IRINOTECAN;
L 001281814;
LENALIDOMIDE;
MITOXANTRONE;
NALPHA (4 AMINO 4 DEOXYPTEROYL) NDELTA HEMIPHTHALOYLORNITHINE;
PACLITAXEL;
SUNITINIB;
TEMOZOLOMIDE;
UNCLASSIFIED DRUG;
ACUTE GRANULOCYTIC LEUKEMIA;
ADULT;
AGED;
ANTIBODY PRODUCTION;
ANTIBODY TITER;
ARTICLE;
CHILL;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DESQUAMATION;
DRUG DOSE ESCALATION;
DRUG ERUPTION;
DRUG HALF LIFE;
DRUG RESPONSE;
DYSPNEA;
EDEMA;
FATIGUE;
FEMALE;
FEVER;
HUMAN;
HYPERBILIRUBINEMIA;
HYPERGLYCEMIA;
HYPOALBUMINEMIA;
HYPOCALCEMIA;
HYPOTENSION;
HYPOXIA;
LEUKEMIA REMISSION;
MALE;
MAXIMUM TOLERATED DOSE;
MUSCLE WEAKNESS;
MYELODYSPLASIA;
NAUSEA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROTEIN DOMAIN;
REMISSION;
RIGOR;
SIDE EFFECT;
SINUS TACHYCARDIA;
SUPRAVENTRICULAR TACHYCARDIA;
VOMITING;
WEIGHT GAIN;
ADULT;
AGED;
AGED, 80 AND OVER;
DIPHTHERIA TOXIN;
FEMALE;
HUMANS;
INTERLEUKIN-3;
ISOANTIBODIES;
LEUKEMIA, MYELOID, ACUTE;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
MYELODYSPLASTIC SYNDROMES;
RECOMBINANT FUSION PROTEINS;
REMISSION INDUCTION;
SALVAGE THERAPY;
TREATMENT OUTCOME;
|
|
EID: 39749148257
PISSN: 10428194
EISSN: 10292403
Source Type: Journal
DOI: 10.1080/10428190701799035 Document Type: Article |
|
Times cited : (131)
|
|
References (39)
|
